InflaRx N.V. (IFRX) News
Filter IFRX News Items
IFRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IFRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IFRX News From Around the Web
Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.
InflaRx Announces Participation in January Events in San FranciscoJENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showc |
US Penny Stocks To Watch In December 2024As the U.S. stock market heads into the Christmas break, optimism is in the air with major indices like the Nasdaq Composite and S&P 500 posting gains, sparking hopes for a Santa Claus rally to close out 2024. Penny stocks may be considered a throwback term, yet they continue to offer intriguing opportunities for those looking beyond well-known names. Often representing smaller or newer companies, these stocks can provide growth potential at lower price points when supported by strong... |
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are pleased to have started our Phase |
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where InflaRx N.V. (NASDAQ:IFRX) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […] |
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeJENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respirato |
Prenetics Global And 2 Other US Penny Stocks To WatchAs the post-election stock market rally loses steam, major indexes in the United States have shown mixed results, reflecting investor uncertainty amid fluctuating interest rates and inflation data. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential value and growth opportunities. Though the term "penny stocks" may seem outdated, these investments can still offer unique prospects when backed by strong financials... |
InflaRx Reports Q3 2024 Financial Results and ProgressInflarx N.V. ( (IFRX) ) has released its Q3 earnings. Here is a breakdown of the information Inflarx N.V. presented to its investors. InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics, particularly targeting the complement system, with its lead product candidate being vilobelimab. The company recently released its third-quarter 2024 financial results, showcasing significant milestones in their clinical trials and ongoing financial stability. Key hig |
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
InflaRx expects cash to fund operations into 2026As of September 30, 2024, InflaRx’s (IFRX) total available funds amounted to EUR 62.0 million, composed of EUR 26.2 million in cash and cash equivalents and EUR 35.8 million in marketable securities. From the EUR 26.2 million cash and cash equivalents, EUR 4.2 million are held in EURO and EUR 24.6 million are held in USD, this is equivalent to EUR 22.0 million at an exchange rate of 1.1196 on 30 September 2024. All marketable securities are held in USD and have a nominal value of $40.5 million. |
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue EstimatesInflaRx (IFRX) delivered earnings and revenue surprises of -22.22% and 195.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |